Business Context and Reporting Period
This Form 8-K, dated September 17, 2007, reports the completion of a reverse merger between Transdel Pharmaceuticals, Inc. ("Transdel") and Trans-Pharma Corporation ("Trans-Pharma"). Transdel, previously a shell company focused on mineral exploration, has disposed of its former assets and liabilities via a split-off. Post-merger, Transdel operates as a specialty pharmaceutical company focused on the development of topically administered medications, specifically its lead candidate, Ketotransdel™, a transdermal NSAID formulation.
Key Financial Metrics
- Capital Raised: Approximately $3.7 million in net proceeds from a Private Placement of 40.9 units (consisting of common stock and warrants) completed immediately following the merger. An additional $100,000 in subscriptions was accepted on September 18, 2007.
- Cash Position: As of June 30, 2007, the company held $1.4 million in cash. Post-merger liquidity is expected to fund operations through the first quarter of 2008.
- Historical Losses: Since inception through June 30, 2007, the company has incurred aggregate losses of $3.2 million, primarily due to general and administrative and research and development expenses.
- Debt: $1.5 million in convertible notes held by Trans-Pharma were assumed by Transdel and converted into 1,530,177 shares of common stock immediately following the merger.
- Capital Structure: Following the merger, private placement, and split-off, 13,427,004 shares of common stock were issued and outstanding. The company also issued 600,000 stock options and 545,458 warrants.
Material Changes
- Reverse Merger: Trans-Pharma became a wholly-owned subsidiary of Transdel. The transaction is accounted for as a reverse merger and recapitalization of Trans-Pharma, meaning historical financial statements will reflect Trans-Pharma's operations.
- Management Change: Rolf Harms resigned as the sole officer and director. The new board consists of Juliet Singh, Ph.D. (CEO) and Jeffrey J. Abrams, M.D. (Director).
- Asset Disposition: Transdel transferred all pre-merger assets and liabilities to a subsidiary, Bywater Resources Holdings, Inc., which was subsequently split off to a major stockholder in exchange for the cancellation of 5,550,007 shares of Transdel stock.
- Accounting Change: The company changed its fiscal year-end from May 31 to December 31, effective September 17, 2007.
- Accountant Change: Webb & Company, P.A. was dismissed as the independent auditor and replaced by KMJ | Corbin & Company LLP, the former auditor of Trans-Pharma.
Guidance, Outlook, and Risks
Outlook and Guidance: Management expects to file an Investigational New Drug (IND) application for Ketotransdel™ with the FDA by the end of 2007 or beginning of 2008. Phase 3 clinical trials are anticipated to begin in the first or second quarter of 2008, with completion expected 6-9 months thereafter. The company believes current capital resources will sustain operations through Q1 2008, but additional financing will be required to execute the full 2008 operating plan.
Risks and Contingencies:
- Going Concern: The independent auditor expressed substantial doubt about the company's ability to continue as a going concern in the 2006 audit due to a history of losses and reliance on future financing.
- Regulatory Approval: There is no assurance that the FDA will approve the proposed clinical trials or the drug itself. Delays in FDA approval or manufacturing could materially harm the business.
- Financing: The company has limited funds and may be forced to delay or terminate clinical trials if additional capital is not available on favorable terms.
- Market Acceptance: Even if approved, there is no guarantee the market will accept the product, particularly given competition from established oral NSAIDs and other transdermal systems.
Investor Verification Checklist
- Verify the effectiveness of the resale registration statement for the Private Placement shares, as failure to register could limit liquidity for investors.
- Confirm the timeline for the filing of the IND application and the commencement of Phase 3 trials, as delays are a primary risk factor.
- Monitor the company's cash burn rate and the status of any additional financing efforts required to fund operations beyond Q1 2008.
- Review the terms of the warrants issued in the Private Placement, specifically the anti-dilution provisions that adjust the exercise price if shares are issued below $2.00.
- Assess the company's ability to maintain compliance with FDA Good Manufacturing Practices (cGMP) given its reliance on third-party manufacturers.